OP0345 Denosumab compared with risedronate in glucocorticoid-treated subjects: results from the final 24-month analysis of a randomised, double-blind, double-dummy study

Abstract

Denosumab 60 mg subcutaneously Q6M increased spine and hip BMD significantly more than risedronate 5 mg orally QD at 12 months in glucocorticoid-treated subjects (as previously reported). This analysis compared the BMD effects of denosumab vs. risedronate and further characterized denosumab safety in this population at 24 months. This phase 3, randomized, double-blind, double-dummy study enrolled adults C 18 years receiving C 7.5 mg daily prednisone (or equivalent) for\3 months (glucocorticoid-initiating subpopulation) or C 3 months (glucocorticoid-continuing subpopulation). All subjects\ 50 years had history of osteoporotic fracture. Glucocorticoidcontinuing subjects C 50 years had lumbar spine (LS), total hip (TH), or femoral neck BMD T-scores B-2.0, or B-1.0 and history of fracture. Subjects were randomized 1:1 to denosumab 60 mg subcutaneously Q6M or risedronate 5 mg orally QD for 24 months. This analysis assessed denosumab superiority over risedronate for percentage change from baseline in LS and TH BMD at 24 months. Of 795 randomized subjects, 590 (74.2%) completed the 24-month study (glucocorticoid-initiating: 109/145 denosumab, 117/145 risedronate; glucocorticoid-continuing: 186/253 denosumab, 178/252 risedronate). Denosumab was superior to risedronate for increases from baseline in LS and TH BMD at all timepoints assessed through 24 months in each subpopulation (Figure). Adverse events, serious adverse events (including infection), and fractures were similar between groups. (Figure presented) In conclusion, denosumab was superior to risedronate for increases in spine and hip BMD through 24 months. The overall safety profile was similar between groups. Denosumab may offer a valuable osteoporosis treatment option for patients receiving glucocorticoids.